Events

IAS 2023 SATELLITE SESSION | PREPARING FOR THE INTRODUCTION OF INJECTABLE CABOTEGRAVIR FOR HIV PREVENTION IN ASIA

This IAS 2023 session will review evidence from recent studies designed to inform CAB PrEP introduction in Asia; identify regional priorities for a CAB implementation science agenda; examine regional lessons from oral PrEP introduction and scale-up; highlight progress and lessons from preparing for CAB rollout in Africa; and introduce available policy and program planning tools and resources to help countries prepare for CAB rollout.

Continue Reading

Blog

WE NEED TO APPLY A GENDER-TRANSFORMATIVE LENS TO PrEP MARKETING

As marketing for PrEP has evolved, we have seen a shift away from strategies we know don’t work: fear-based, stigma-reinforcing, HIV-centric, medicalized, and far-future focused. Yet we need to go a step further and analyze all the insights that form the backbone of our campaigns and our messages through a gender-transformative lens.

Continue Reading

Blog

POSITIONING PrEP FOR SUCCESS: SIX KEY LESSONS

Demand for oral PrEP has been an issue. How can we do marketing differently with a multi-product PrEP portfolio? What do we want young women’s hearts to feel—and minds to think—about PrEP? These question about the positioning of PrEP are central to its branding as a multi-product category.

Continue Reading

Events

CHAMPIONING CHOICE IN A MULTI-PRODUCT HIV PREVENTION MARKET

New products, including the dapivirine vaginal ring and injectable cabotegravir, have been approved in several countries, and more biomedical prevention products are in development. As the catalog of HIV prevention products expands, so too does the conversation about the importance of upholding choice to optimize the benefits for potential PrEP users.

Continue Reading

Blog

A NEW OPTION TO TRANSFORM HIV PREVENTION

The future of HIV prevention is here. Injectable cabotegravir (CAB) is the most effective, longest-acting option for avoiding the virus. Until now, pre-exposure prophylaxis (or PrEP) medicine taken to prevent HIV has only been available as an oral pill that must be taken daily. CAB needs to be injected only once every two months.

Continue Reading